DESTINY-Breast04 Latest Test Results
ADC评论
June 29, 2022
Breast cancer is the most common cancer and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million cases of
Author: ADC评论
Features of ADC Cytotoxins
ADC评论
June 29, 2022
The physicochemical properties of toxins directly affect the ability of ADCs to kill target cells. Therefore, ADC cytotoxins usually have the following characteristics:(1) The mechanism
Characteristics of ADC targets
ADC评论
June 28, 2022
The target identification of ADC drugs plays a decisive role in the drugability of ADCs. Qualified ADC targets should have:(1) Tissue specificity: In order to
FDA: Development of Oligonucleotide Therapeutics Guidance
ADC评论
June 28, 2022
I. INTRODUCTION This guidance provides recommendations to assist industry in the development of oligonucleotide therapeutics under section 505 of the Federal Food, Drug, and Cosmetic
Technical Characteristics Of Three Stages Of ADC
ADC评论
June 27, 2022
The first generation: represented by Mylotarg, with high off-target toxicity and low drug efficacy Mylotarg It is the world’s first marketed ADC drug, the first
The World’s First Targeted HBsAg Cell Therapy Obtained Clinical Proof Of Concept Announced
ADC评论
June 27, 2022
On June 23, Xinghand Bio announced that the company first announced its targeting hepatitis B virus surface antigen (HBsAg) at the 57th European Association for
CD19 CAR-T brings a major breakthrough in the treatment of LBCL
ADC评论
June 25, 2022
On June 24, BMS announced that the FDA approved a new indication of the CD19 CAR-T therapy Breyanzi (lisocabtagene maraleucel) for the second-line treatment of
The Main Representative ADC Drugs In The World
ADC评论
June 25, 2022
1. Pfizer: Pioneer in the field of ADC, launched the world’s first ADC drug Mylotarg Mylotarg (Gemtuzumabozogamicin, gemtuzumab) was originally developed by Pfizer. It is
Shionogi 3CL protein inhibitor has been suspended by Japan’s PMDA
ADC评论
June 24, 2022
On June 22, several Japanese media, including the Mainichi Shimbun, reported that Shionogi’s S-217622 emergency authorization application based on Phase II data was suspended by
Core Elements Affecting ADC Drug
ADC评论
June 24, 2022
1. Selection of the correct target The successful development of ADC relies on the specific binding of antibodies to the target antigen. The ideal ADC
Cetuximab Approved In China For Locally Advanced Head And Neck Squamous Cell Carcinoma
ADC评论
June 23, 2022
On June 22, Merck announced that Erbitux® (cetuximab injection) was officially approved by the China National Medical Products Administration (NMPA) for the treatment of locally
Future Development Prospects of Antibody Drug Conjugates
ADC评论
June 23, 2022
Due to the advantages of clear targets, mature technology and good selectivity, the research of antibody-drug conjugates is expected to continue to become a research
